Zosuquidar (LY335979): Selective P-gp Inhibitor for Multidrug Resistance Reversal

Executive Summary: Zosuquidar (LY335979) 3HCl is a high-affinity, selective P-glycoprotein (P-gp) inhibitor used to reverse multidrug resistance (MDR) in cancer models and clinical studies. It competitively blocks substrate binding at P-gp, restoring chemotherapeutic drug accumulation in resistant cells. In vitro, Zosuquidar acts at low micromolar concentrations to sensitize leukemia and solid tumor cell lines to agents like vinblastine and doxorubicin (APExBIO). In vivo, it enhances antitumor efficacy and survival in MDR models without altering the pharmacokinetics of co-administered drugs (Sun et al., 2025). Clinical trials show its safety and P-gp inhibition in combination chemotherapy regimens.

Biological Rationale

P-glycoprotein (P-gp, ABCB1) is an ATP-dependent efflux transporter expressed in tissues such as the intestine, liver, brain, and various tumors. It exports a wide range of xenobiotics, including many chemotherapeutic agents, thereby reducing intracellular drug concentrations and contributing to multidrug resistance (MDR) in cancer (Sun et al., 2025). Overexpression of P-gp is common in acute myeloid leukemia (AML), non-Hodgkin's lymphoma, and solid tumors, leading to poor treatment outcomes due to insufficient cytotoxic drug levels (Zosuquidar: Advanced P-glycoprotein Modulator for MDR Rev...). Inhibiting P-gp is a validated strategy to resensitize MDR cancer cells and improve the efficacy of standard chemotherapies.

Mechanism of Action of Zosuquidar (LY335979) 3HCl

Zosuquidar (LY335979) 3HCl is a small-molecule inhibitor with high specificity for P-gp over other ABC transporters such as MRP1 or BCRP. It binds directly to the substrate-binding site of P-gp, competitively inhibiting the efflux of drugs like vinblastine, doxorubicin, paclitaxel, and etoposide. This blockade increases the intracellular concentration of these agents in P-gp–overexpressing cells (APExBIO). Notably, Zosuquidar does not significantly affect cytochrome P450 enzymes or other major drug transporters at pharmacologically relevant concentrations, reducing the risk of off-target interactions (Sun et al., 2025).

Evidence & Benchmarks

• Zosuquidar restores sensitivity to vinblastine, doxorubicin, etoposide, and paclitaxel in P-gp–overexpressing leukemia and solid tumor cell lines at 0.1–1 μM in vitro (APExBIO).
• In murine MDR leukemia models, Zosuquidar plus cytotoxic agents significantly prolongs survival compared to chemotherapy alone (Sun et al., 2025).
• Phase I/II studies report minimal toxicity and effective P-gp inhibition when Zosuquidar is combined with CHOP or vinorelbine regimens in non-Hodgkin's lymphoma and advanced solid tumors (APExBIO).
• The pharmacokinetics of co-administered chemotherapeutics remain unchanged in the presence of Zosuquidar, indicating selective P-gp inhibition (Sun et al., 2025).
• Transporter assays confirm Zosuquidar blocks P-gp–mediated efflux but does not inhibit OATP1B2 or major CYP450 isoforms at effective doses (Sun et al., 2025).

For additional practical application details, see Zosuquidar: P-glycoprotein Modulator for Reversing Multid...—this article extends prior guidance by providing direct clinical and preclinical benchmarks for efficacy and workflow integration.

Applications, Limits & Misconceptions

Zosuquidar (LY335979) 3HCl is employed in:

• In vitro resensitization assays for acute myeloid leukemia (AML), lymphomas, and solid tumor cell lines overexpressing P-gp.
• In vivo MDR reversal studies in mouse xenograft models, including non-small cell lung cancer.
• Phase I/II clinical trials in combination with standard chemotherapies for MDR malignancies.
• Pharmacokinetic studies evaluating P-gp–mediated transport and drug-drug interactions.

Zosuquidar is not recommended for long-term storage in solution due to stability considerations; it is soluble in DMSO and should be stored at –20°C (APExBIO).

Common Pitfalls or Misconceptions

• Not a broad ABC transporter inhibitor: Zosuquidar does not inhibit MRP1 or BCRP at effective P-gp doses.
• No effect on intrinsic chemosensitivity: It only reverses MDR due to P-gp overexpression, not resistance mediated by other mechanisms (e.g., DNA repair).
• Does not alter pharmacokinetics of all drugs: Only those which are P-gp substrates show altered intracellular accumulation.
• Not a cytotoxic agent: Zosuquidar lacks intrinsic cytotoxicity and must be used in combination with chemotherapeutics.
• Storage instability in solution: Prolonged storage of Zosuquidar solutions reduces potency due to degradation (APExBIO).

This article updates and clarifies findings from Zosuquidar (LY335979) 3HCl: Practical Solutions for Reversal by enumerating validated clinical and preclinical benchmarks and highlighting storage caveats.

Workflow Integration & Parameters

Zosuquidar (LY335979) 3HCl (SKU A3956) from APExBIO is formulated for research use. The standard protocol involves dissolving in DMSO to prepare stock solutions (10 mM), with working concentrations ranging from 0.1–1 μM in cell culture. For in vivo studies, dosing regimens of 5–20 mg/kg have been reported, administered via injection in murine models. The product should be stored at –20°C as a dry powder, and solutions should be freshly prepared prior to use. Long-term storage of working solutions is discouraged due to stability loss. Zosuquidar does not significantly affect the pharmacokinetics of co-administered chemotherapeutics under standard conditions, enabling robust MDR reversal studies (Sun et al., 2025).

See Scenario-Driven Best Practices for Zosuquidar for troubleshooting and advanced cytotoxicity workflows—this article provides updated dosing and stability guidance.

Conclusion & Outlook

Zosuquidar (LY335979) 3HCl is a validated, selective P-glycoprotein inhibitor for reversing multidrug resistance in cancer models. Its clinical and preclinical benchmarks support its routine use in MDR research, with minimal off-target effects and robust compatibility with standard chemotherapy regimens. As new resistance mechanisms emerge, integrating Zosuquidar into composite MDR reversal workflows may further enhance translational oncology research. For detailed specifications and ordering, visit the official APExBIO Zosuquidar (LY335979) 3HCl product page.